This topic contains a solution. Click here to go to the answer

Author Question: The nigrostriatal pathway uses the neurotransmitter a. dopamine, and is important in movement. b. ... (Read 78 times)

sheilaspns

  • Hero Member
  • *****
  • Posts: 567
The nigrostriatal pathway uses the neurotransmitter
 
  a. dopamine, and is important in movement.
 b. dopamine, and is important in the development of Parkinson's disease.
  c. norepinephrine, and is important in vigilance.
 d. serotonin, and is important in mood.

Question 2

Behaviors involving motivated behaviors and the processing of rewards often involve brain systems that use the neurotransmitter
 
  a. dopamine.
 b. norepinephrine.
  c. epinephrine.
 d. serotonin.



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

AaaA

  • Sr. Member
  • ****
  • Posts: 339
Answer to Question 1

b

Answer to Question 2

a





 

Did you know?

Persons who overdose with cardiac glycosides have a better chance of overall survival if they can survive the first 24 hours after the overdose.

Did you know?

The tallest man ever known was Robert Wadlow, an American, who reached the height of 8 feet 11 inches. He died at age 26 years from an infection caused by the immense weight of his body (491 pounds) and the stress on his leg bones and muscles.

Did you know?

Since 1988, the CDC has reported a 99% reduction in bacterial meningitis caused by Haemophilus influenzae, due to the introduction of the vaccine against it.

Did you know?

Stevens-Johnson syndrome and Toxic Epidermal Necrolysis syndrome are life-threatening reactions that can result in death. Complications include permanent blindness, dry-eye syndrome, lung damage, photophobia, asthma, chronic obstructive pulmonary disease, permanent loss of nail beds, scarring of mucous membranes, arthritis, and chronic fatigue syndrome. Many patients' pores scar shut, causing them to retain heat.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

For a complete list of videos, visit our video library